Page 17 - Journal of Structural Heart Disease Volume 5, Issue 1

Case Report
6
References
1. Wolf PA, Dawber TR, Thomas HE Jr, Kan- nel WB. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study. Neurol- ogy. 1978;28:973-977. DOI: 10.1212/ WNL.28.10.973
2. Hart RG, Pearce LA, Aguilar MI. Meta-anal- ysis: antithrombotic therapy to prevent stroke in patients who have nonvalvu- lar atrial fibrillation. Ann Intern Med. 2007;146:857-867. DOI: 10.7326/0003- 4819-146-12-200706190-00007
3. Guerios EE, Gloekler S, Schmid M, Khattab A, Nietlispach F, Meier B. Double device left atrial appendage closure. EuroInter- vention. 2015;11:470-476. DOI: 10.4244/ EIJY14M07_03
4. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrilla- tion of the European Society of Cardiology (ESC). Eur Heart J. 2010;31:2369-2429. DOI: 10.1093/eurheartj/ehq278
5. Sandercock P, Bamford J, Dennis J, Burn J, Slattery J, Jones L, et al. Atrial fibrillation and stroke: prevalence in different types of stroke and influence on early and long term prognosis (Oxfordshire Community Stroke Project). BMJ. 1992;305:1460–1465. DOI: 10.1136/bmj.305.6867.1460
6. Blackshear JL, Odell JA. Appendage oblit- eration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann Thorac Surg. 1996;61:755-759. DOI: 10.1016/0003- 4975(95)00887-X
7. Brass LM, Krumholz HM, Scinto JM, Radford M. Warfarin use among patients with atrial fibrillation. Stroke. 1997;28:2382–2389. DOI: 10.1161/01.STR.28.12.2382
8. Reddy VY, Doshi SK, Sievert H, Buchbind- er M, Neuzil P, Huber K, et al. PROTECT AF Investigators. Percutaneous left atrial ap- pendage closure for stroke prophylaxis in
patients with atrial fibrillation: 2.3-year fol- low-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Pro- tection in Patients with Atrial Fibrillation) Trial. Circulation. 2013;127:720-729. DOI: 10.1161/CIRCULATIONAHA.112.114389
9. Reddy VY, Holmes D, Doshi SK, et al. Safety of percutaneous left atrial appendage clo- sure: results from the Watchman Left Atrial Appendage System for Embolic Protection in Patients with AF (PROTECT AF) clinical trial and the Continued Access Regis- try. Circulation. 2011;123:417-424. DOI: 10.1161/CIRCULATIONAHA.110.976449
10. Holmes DR Jr, Kar S, Price MJ, Whisenant B, Sievert H, Doshi SK, et al. Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J Am Coll Cardiol. 2014;8;64:1-12. DOI: 10.1016/j.jacc.2014.04.029
11. Reddy VY, Mobius-Winkler S, Miller MA, et al. Left Atrial Appendage Closure With the Watchman Device in Patients With a Contraindication for Oral Anticoagulation: The ASAP Study (ASA Plavix Feasibility Study With Watchman Left Atrial Append- age Closure Technology). J Am Coll Car- diol. 2013;61:2551-2556. DOI: 10.1016/j. jacc.2013.03.035
12. Veinot JP, Harrity PJ, Gentile F, Khandhe- ria BK, Bailey KR, Eickholt JT, et al. Anato- my of the normal left atrial appendage: A quantitative study of age-related chang- es in 500 autopsy hearts: Implications for echocardiographic examination. Circula- tion 1997;96:3112–3115. DOI: 10.1161/01. CIR.96.9.3112
13. Hara H, Virmani R, Holmes DR, Buchbind- er M, Lesser JR, Van Tassel RA, et al. Is left atrial appendage more than a simple appendage? Catheter Cardiovasc Interv. 2009;74:234-242. DOI: 10.1002/ccd.21983
14. Su P, McCarthy KP, Ho SY. Occluding the left atrial appendage: anatomical consider- ations, Heart. Vol. 94, no. 9, pp. 1166–1170, 2008. DOI: 10.1136/hrt.2006.111989
15. Viles-Gonzalez JF, Kar S, Douglas P, Duk- kipati S, Feldman T, Horton R, et al. The clinical impact of incomplete left atrial appendage closure with the Watchman device in patients with atrial fibrillation. J Am Coll Cardiol. 2012;59:923-929. DOI: 10.1016/j.jacc.2011.11.028
16. Viles-Gonzalez JF, Reddy VY, Petru J, Mraz T, Grossova Z, Kralovec S, Neuzil P. Incom- plete occlusion of the left atrial appendage with the percutaneous left atrial append- age transcatheter occlusion device is not associated with increased risk of stroke. Journal of interventional cardiac electro- physiology : an international journal of ar- rhythmias and pacing. 2012;33:69-75. DOI: 10.1007/s10840-011-9613-x
17. Wunderlich N, Wilson N, Sievert, H. A nov- el approach to treat residual peridevice leakage after left atrial appendage closure. Cathet Cardiovasc Intervent. 2013;82:313- 319. DOI: 10.1002/ccd.23014
18. Cruz-Gonzalez I, Yan BP, Lam YY. Left atri- al appendage exclusion: state-of-the-art. Catheter Cardiovasc Interv. 2010;75:806- 813. DOI: 10.1002/ccd.22344
19. Liu Z, Yu J, Fang PH, He J, Wang JD, Wang H, et al. Double device left atrial append- age closure with the WATCHMANTM . Int J Cardiol. 2015;187:281-282. DOI: 10.1016/j. ijcard.2015.03.289
Journal of Structural Heart Disease, February 2019
Volume 5, Issue 1:1-6
Cite this article as: Alsmadi F, Shah MA, Qattea MB. Left Atrial Appendage Closure with Double Watchman De- vices: A Case Report. Structural Heart Disease. 2019;5(1):1-6. DOI: https://doi. org/10.12945/j.jshd.2019.010.18